BASIC AND CLINICAL STUDIES ON TE-031 (A-56268)

TE-031 (A-56268) is a semi-synthetic macrolide derivative of erythromycin. Its most important characteristic is that, because of good absorption after oral administration, it achieves high concentrations in blood and various tissues. In a Phase-I trial on TE-031, decrease in WBC, platelets, and hemo...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 36; no. Supplement3; pp. 594 - 599
Main Authors KUMADA, TEPPEI, SHIMIZU, KIHACHIRO, FUKADA, TOMOKO, KATAHIRA, JUNICHI
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1988
公益社団法人 日本化学療法学会
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.36.Supplement3_594

Cover

More Information
Summary:TE-031 (A-56268) is a semi-synthetic macrolide derivative of erythromycin. Its most important characteristic is that, because of good absorption after oral administration, it achieves high concentrations in blood and various tissues. In a Phase-I trial on TE-031, decrease in WBC, platelets, and hemoglobin contents were detected in a few cases. We therefore investigated the effects of the drug on human hematopoietic stem cells by clonal assay, using the colony method. We found that TE-031 suppressed the granulocyte and megakaryocyte series, erythroid stem cells and mixed colony-forming stem cells. Erythromycin, the control drug, suppressed only late-stage erythroid stem cells (CFU-E). In a clinical study, the hemoglobin level dropped in one subject. This suggests that TE-031 may cause hematocytopenia by suppressing hematopoietic stem cells. The clinical efficacy rate of TE-031 in the treatment of respiratory tract infections was 64%, and we conclude that it is a useful new antibiotic.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.36.Supplement3_594